Evolving Landscape of Multiple Myeloma: Current and Emerging Therapies for Frontline and Early Relapse : Episode 5
Impact of CAR T-cell therapy in Earlier Lines of MM
A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.
EP: 1.Transplant Eligible Multiple Myeloma: Current Standard of Care and Treatment Landscape
EP: 2.Updates from EHA 2024: Review of PERSEUS and IsKIA
EP: 3.Clinical Implications of Updated Data from EHA 2024
EP: 4.Updated Data from EHA 2024: Transplant Ineligible NDMM
Now Viewing
EP: 5.Impact of CAR T-cell therapy in Earlier Lines of MM
EP: 6.CAR T-cell therapy in MM: Updated Data and the Future
Video content above is prompted by the following:
- Let’s talk about the use of CAR T-cell therapy in early R/R MM. Please share your thoughts on the following data:
- CARTITUDE-4
- KarMMa-3
- How does the CAR T-cell fit into 2nd line treatment in your practice and in which patients do you use CAR T-cell in?
- How does CAR T-cell therapy in the 2nd line affect your approach to front-line therapy for MM?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
